Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V. Ellen Maher(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Harpreet Singh, Michael H. Brave(United States Food and Drug Administration), James Xu(United States Food and Drug Administration), Daniel L. Suzman(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Marc R. Theoret(United States Food and Drug Administration), Kirsten B. Goldberg(United States Food and Drug Administration), Laura L. Fernandes(United States Food and Drug Administration), Chana Weinstock(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Sundeep Agarwal(United States Food and Drug Administration), Yang‐Min Ning(United States Food and Drug Administration), Julia A. Beaver(Center for Drug Evaluation and Research)
Cited by 348
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k